A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease.
This pilot clinical trial was a 15-week, double-blind, controlled, three-way crossover study evaluating cognitive effects of ceranapril in subjects with dementia of the Alzheimer type (age range 50-75 years). Computerized (CNTB) and noncomputerized cognitive test batteries revealed no significant results (p > 0.05). On further analysis of the data, however, a study of longer duration and/or higher dosages may be warranted.
Sudilovsky
A
A
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey.
Cutler
N R
NR
Sramek
J J
JJ
Wardle
T
T
Veroff
A E
AE
Mickelson
W
W
Markowitz
J
J
Repetti
S
S
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D010865:Pilot Projects; D011392:Proline / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000806:Angiotensin-Converting Enzyme Inhibitors; D009943:Organophosphorus Compounds; D011392:Proline; C054518:ceronapril